Citi’s strategic investment vehicle helped fill out a series D round valuing the risk management software developer above $1bn.

ANZi Ventures was among the investors that added $100m to a round that now values the cross-border payment software producer at $2.6bn.

Poly Group unit Poly Huixin Fund Investment Management was among the new investors for the industrial cybersecurity software provider.

Qualcomm Ventures has returned to back the e-commerce platform developer’s series D round after co-leading its previous round late last year.

The health benefits provider raised $28m in a series D round led by Axa Venture Partners to take its overall funding past $75m.

The identity verification platform developer was valued at $1.3bn in a round featuring Synchrony Financial, Citi Ventures and Wells Fargo Strategic Capital.

OSF Healthcare Ventures contributed to a $102m series D round for Inflammatix, a developer of diagnostics systems for detecting infections.

Novo Nordisk, Insulet and Mayo Clinic helped the diabetes monitoring technology provider push its overall funding past $100m.

D1 Capital Partners has led a $102m series D round for Inflammatix, whose existing shareholders include Stanford-StartX Fund.

The insurance comparison platform developer has added Jungle Ventures funding to cash from investors including American Family and MassMutual.